NASDAQ$AMGN

Amgen Inc · Q1 2020 earnings

Q1 2020 earnings · · Investor relations

Briefing

Amgen's financial performance was driven by increased unit demand, offset by lower net selling prices.

Amgen reported an 11% increase in total revenues to $6.2 billion for Q1 2020 compared to Q1 2019. GAAP EPS decreased by 3% to $3.07, while non-GAAP EPS increased by 17% to $4.17. The company generated $2.0 billion in free cash flow during the quarter and reaffirmed its 2020 total revenue guidance.

  • Total revenues increased by 11% to $6.2 billion due to higher unit demand.
  • GAAP EPS decreased by 3% to $3.07, influenced by Otezla acquisition costs.
  • Non-GAAP EPS increased by 17% to $4.17, driven by higher revenues and fewer shares outstanding.
  • The company generated $2.0 billion in free cash flow.

Headline financials

Total Revenue

$6.16B

Previous: $5.56B+10.9%
EPS (adj)

$4.17

Previous: $3.56+17.1%
Capital Expenditures

-$142M

Previous: -$116M-22.4%
Free Cash Flow

$1.68B

Previous: $1.88B-10.3%
Net Income

$1.83B

Previous: $1.99B-8.4%
Operating Income

$2.36B

Previous: $2.47B-4.7%
Gross Profit

$4.65B

Previous: $4.5B+3.2%
Cash & Equivalents

$7.69B

Previous: $7.36B+4.5%
Total Assets

$61.7B

Previous: $64B-3.6%

Revenue & EPS history

Amgen · Revenue · Quarterly

$6.16B

Q1 2020+10.9%vs Q1 2019
Beat estimate in 15 of 16 quarters(94%)
ActualEstimate

Revenue by segment

Amgen · $5.3B total across 15 segments · Q1 2020

  • Enbrel
    $1.15B+0.2%
  • Prolia
    $654M+10.5%
  • Neulasta
    $609M-40.4%
  • XGEVA
    $481M+2.1%
  • Otezla
    $479M
  • Aranesp
    $422M+1.9%
  • KYPROLIS
    $280M+14.3%
  • Repatha
    $229M+62.4%
  • Nplate
    $218M+15.3%
  • Vectibix
    $202M+18.8%
  • Parsabiv
    $175M+38.9%
  • MVASI
    $115M
  • EVENITY
    $100M+488.2%
  • BLINCYTO
    $94M+36.2%
  • AMJEVITA/AMGEVITA
    $86M

Forward guidance

Amgen reaffirmed its full-year 2020 guidance for total revenues and non-GAAP EPS.

Tailwinds

  • Total revenues are expected to be in the range of $25.0 billion to $25.6 billion.
  • GAAP EPS is projected to be between $10.65 and $11.45.
  • The GAAP tax rate is anticipated to be in the range of 10.5% to 11.5%.
  • Non-GAAP EPS is expected to be in the range of $14.85 to $15.60.
  • The non-GAAP tax rate is projected to be between 13.5% and 14.5%.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2020

Historical avgQ1 2020

+0.3%

Avg return

Earnings day

+0.0%

Avg return

5 days after

+0.1%

Avg return

30 days after

53%

39 / 73 earnings

Positive

+12.2%

Q1 2024

Best reaction

-8.7%

Q3 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.9%-4.4%-2.7%
Q4 2025+3.0%+11.0%+9.1%
Q3 2025+7.7%+9.1%+11.2%
Q2 2025-5.1%-5.0%-5.5%
Q1 2025-1.1%-2.8%+1.6%
Q4 2024+6.5%+2.0%+12.4%
Q3 2024+1.3%+0.3%-10.5%
Q2 2024-3.9%-0.8%-0.3%
Q1 2024+12.2%+8.3%+10.3%
Q4 2023-8.1%-9.6%-15.3%
Q3 2023-0.9%+2.5%+2.5%
Q2 2023+5.6%+13.2%+11.4%
Q1 2023+0.4%-1.2%-9.2%
Q4 2022-2.1%-2.6%-6.7%
Q3 2022+0.0%+8.7%+6.1%
Q2 2022-0.4%+0.5%-1.9%
Q1 2022-4.7%-7.6%+2.2%
Q4 2021+8.5%+2.7%+4.2%
Q3 2021+4.0%+1.9%-4.1%
Q2 2021-4.8%-4.0%-5.8%
Q1 2021-7.4%-6.2%-7.9%
Q4 2020-1.4%-1.7%-7.7%
Q3 2020-2.5%-1.5%+0.6%
Q2 2020-1.9%-3.5%-0.3%
Q1 2020-2.0%+0.3%-2.5%
Q4 2019-4.9%-2.4%-12.1%
Q3 2019+2.9%+6.3%+14.4%
Q2 2019+6.0%+6.3%+17.5%
Q1 2019-2.8%-2.1%-6.7%
Q4 2018-3.7%-2.5%-1.0%
Q3 2018+2.4%-0.6%+7.5%
Q2 2018-0.3%+1.8%+1.9%
Q1 2018+0.1%+1.6%+1.9%
Q4 2017+0.5%-5.1%-0.5%
Q3 2017-2.1%-3.2%-5.7%
Q2 2017-2.9%-3.6%-6.1%
Q1 2017-1.2%-1.3%-5.9%
Q4 2016+4.9%+4.5%+12.9%
Q3 2016-8.7%-11.5%-8.5%
Q2 2016+2.2%+3.9%+2.6%
Q1 2016-1.7%
Q4 2015+1.5%
Q3 2015-0.9%
Q2 2015+3.0%
Q1 2015+1.9%
Q4 2014-3.2%
Q3 2014+6.7%
Q2 2014+6.0%
Q1 2014-3.2%
Q4 2013+0.5%
Q3 2013+1.8%
Q2 2013-1.0%
Q1 2013-7.5%
Q4 2012-0.8%
Q3 2012+0.8%
Q2 2012+7.6%
Q1 2012+0.2%
Q4 2011-0.8%
Q3 2011+4.9%
Q2 2011-3.0%
Q1 2011-1.5%
Q4 2007+0.7%
Q4 2010+0.7%
Q3 2008+0.7%
Q3 2010-0.9%
Q2 2010-0.4%
Q1 2009+1.5%
Q1 2010+1.2%
Q4 2009+0.5%
Q3 2009+1.6%
Q4 2008+3.8%
Q2 2009+3.8%
Q2 2008+3.8%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro